Last reviewed · How we verify
Zerdol (SERTINDOLE)
At a glance
| Generic name | SERTINDOLE |
|---|---|
| Sponsor | H. Lundbeck A/S |
| Drug class | sertindole |
| Target | 5-hydroxytryptamine receptor 2C |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1996 |
Approved indications
- Schizophrenia
Common side effects
Key clinical trials
- An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)
- Antipsychotic Induced Structural and Functional Brain Changes (PHASE4)
- The Effect of Sertindole and Risperidone on Endophenotypic Markers of Schizophrenia (PHASE4)
- Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients (PHASE4)
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
- Safety Study of an Antipsychotic, Sertindole, to Treat Schizophrenia (PHASE4)
- Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis (PHASE3)
- Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zerdol CI brief — competitive landscape report
- Zerdol updates RSS · CI watch RSS
- H. Lundbeck A/S portfolio CI